Health Watch USA Logo COVID-19 Resources & Publications

COVID-19 Resources & References

Back To COVID-19 Home Page

Transcript Of George W. Bush

Pandemic Response

World O Meter   John Hopkins   Projected Deaths  Worker Advocacy   Social Distancing

1.  Lasting Disability after COVID-19 Virus Infection:



Virus Attacks Many Different Organs:

Severe Disease in Children - Kawasaki disease: 


2.  Asymptomatic & Presymptomatic Spread:
Report which Reviews 16 Studies Concludes the Preveillance is Between 40% to 45%:

CDC: Asymptomatic and Presymptomatic Spread: 

Asymptomatic Spread of COVID-19 Nursing Homes: 

Asymptomatic Spread of COVID-19 Cruise Ships

3. Lasting Immunity is In Doubt

Antibody Levels Falling in 3 Months or Less:

COVID-19 Produces Modest Neutralizing Antibodies

--California's Population Does Not Have High Antibodies:

--China's Population Does Not Have High Antibodies:

--England's Population Does Not Have High Antibodies

--Spain's Population Does Not Have High Antibodies

--Sweden's Population Does Not Have High Antibodies:

--Switzerlands' Population Does Not Have High Antibiodies

--USA's Population Does Not Have High Antibodies

Herd Immunity

Reinfections With Virus

4.  Effective & Promissing Treatments:



Dexamethasone -- Reduces Death By 1/3 in Ventilatory Dependent Patients:

Convelescent Plasma:

Antibody Serum:

5.  About Diagnostic Tests:
Summary Articles 

True Pos., False Pos., and False Neg. and True Neg:

6. Disinformation Campaign:
In The United States:

In the European Union:

7. Hydroxychlorquine (HCQ) - Unlikely To Be Effective
FDA Removes Emergency Approval:

EU Governments Ban HCQ for use with COVID-19:

Randomized Controlled Trails -- All Negative.

  • Borba, et al. (Brazil) – RCT. Double Blinded. Hospitalized with severe COVID-19. 18.9% of the patients in the high dose group developed QTc interval abnormalities compared to 11.1% in the low dosage group. The lethality in the high dose group was more than twice that of the low dose control. The study was discontinued. April 24, 2020.
  • Boulware, et al. (USA) – – RCT. Double Blinded. Prophylaxis post exposure to SARS-CoV-2 “After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.” New England Journal of Medicine. June 3, 2020.
  •  Oxford RECOVERY Study: (UK) – RCT. Hospitalized Patients. “There was no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes.” The Trial was halted because of lack of efficacy. June 5, 2020.
  • Skipper, et al. (USA & Canada) – RCT. Double Blind. Non-Hospitalized Patients. “Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.” Annals of Internal Medicine. July 16, 2020. 
  • Cavalcanti, et al. (Brazil) – RCT. Hospitalized Patients. “Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.” New England Journal of Medicine. July 23, 2020.
  • Abella, et al. (USA) RCT. Double Blind Prophylaxis. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Amon Health Care Workers. Benefit not demonstrated. 
  • WHO SOLIDARITY Trail, Pan, et. al. (WHO).  RCT. Adult Hospitalized Patients. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. Benefit not demonstrated.

Negative HCQ Studies - Other:

Positive HCQ Study Withdrawn:

Negative HCQ Study Withdrawn:

8.  Public Wearing Masks
Public Should Wear Masks - How to Prevent Spread: 

  • CDC: 
  • "124 Chinese households found that mask wearing at home by 1 or more family members before the onset of symptoms in the primary case was associated with a lower odds of secondary transmission (adjusted odds ratio, 0.21 [95% CI, 0.06-0.79]).)(1) In a study at a US academic medical center, after the implementation of universal mask use for all health care workers and patients, the SARS-CoV-2 positivity rate among health care workers declined from 14.65% to 11.46%, with a decline of 0.49% per day."(2)  

    • 1) Wang  Y, Tian  H, Zhang  L,  et al.  Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China.   BMJ Glob Health. 2020;5(5):e002794. doi:10.1136/bmjgh-2020-002794 PubMedGoogle Scholar
    • 2) Wang  X, Ferro  EG, Zhou  G, Hashimoto  D, Bhatt  DL.  Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers.   JAMA. 2020;324(7):703-704. doi:10.1001/jama.2020.12897 

Large Meta-analysis Published in the Lancet - 172 Studies:

WHO:  Recommends Public Wear Masks: 

Cloth & DYI Masks Are effective:

Most COPD Patients Can Wear Masks:

Masks Saves Lives

9.  Comorbidity Risk Factors  

10.  Viral Stability
Environmental stability. 

Heat and the Coronovirus: 

Warm Weather and COVID-19 Virus

How soap absolutely annihilates the coronavirus.

Sunlight destroys virus quickly:

12.  Highly Contageous
R0 of 5.7


Dangers of Churches and Singing:


13  Bacterial Secondary Infections
"Half of non-survivors experienced a secondary infection, and ventilator-associated pneumonia occurred in ten (31%) of 32 patients requiring invasive mechanical ventilation." 

Additional CDC resources you may find helpful:

What’s New Page -
Print Resources -
How to protect yourself -
How to protect your family -
Children and Coronavirus Disease 2019 (COVID-19) -
Coronavirus disease 2019 (COVID-19) Checklist: Older Persons.
Are You at Higher Risk for Severe Illness? -
What To Do if You Are Sick -
Personal Protective Equipment (PPE) Burn Rate Calculator -
How to take care of yourself at home -